Personalis Announces Expansion of Scientific and Clinical Team: Deanna Church and Robert Nussbaum

DNA

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc., the leading provider of advanced medical exome and genome sequencing and interpretation services today announced that Deanna Church, Ph.D., has joined its R&D team, and Robert Nussbaum, M.D., Professor of Medicine and Chief of the Division of Genomic Medicine at UCSF, has joined its Clinical and Scientific Advisory Board. Dr. Nussbaum will bring his deep expertise in medical genetics to guide development of Personalis' next-generation sequencing (NGS) based clinical services. Dr. Church comes to Personalis from the NCBI where she helped lead development of the newest Human Reference GRCh38 as well as genomic tools used by scientists worldwide. "We are thrilled that both Dr. Nussbaum and Dr. Church are joining our team," said Personalis Chief Scientific Officer Richard Chen, M.D. "Dr. Nussbaum brings world class expertise to our clinical product development while Dr. Church's deep expertise on the structure of the human genome, scientific tools and databases will help us continue to advance our application of NGS data to research and clinical use."

"We are dedicated to pushing the envelope of accuracy, completeness and clinical utility in human genomic analysis, and Drs. Church and Nussbaum both share our vision and will be instrumental in helping us to advance it"
"We are dedicated to pushing the envelope of accuracy, completeness and clinical utility in human genomic analysis, and Drs. Church and Nussbaum both share our vision and will be instrumental in helping us to advance it," added Personalis CEO John West.

About Personalis

Case Study

[Case Study] Clinical Supply Management

Download this case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study.

Personalis provides researchers and clinicians accurate DNA sequencing and interpretation of human exomes and genomes. We support researchers engaging in case-control, family-based, or proband-only genomic studies of disease, pharmacogenomics, and cancer. Our ACE (Accuracy and Content Enhanced) Technology™ supplements a standard exome or genome, substantially increasing its medically-relevant coverage and accuracy. Personalis builds on this enhanced sequencing foundation with innovative algorithms and proprietary databases for alignment, variant calling, annotation, and analysis. Through this comprehensive approach, we provide genomic data and interpretation of the highest accuracy.

Contacts

Personalis, Inc.
Carol Tillis, 1-650-752-1300
[email protected]
www.personalis.com

Suggested Articles

Myovant’s uterine fibroid drug reduced blood loss in nearly three-quarters of patients, trouncing placebo in the second of two phase 3 studies.

The cystic fibrosis biotech unveiled Belous’ appointment alongside news of the promotion of Geoff Gilmartin to the CMO position.

The series C round is the latest in a series of boosts for Frequency’s attempts to tackle hearing loss through the activation of progenitor cells.